黄芪注射液联合博尔泰力注射液治疗失代偿期肝硬化的临床应用研究  

Clinical study of astragalus injection combined with marine injection treatment in patients with decompensated cirrhosis

作　　者：甘井山[1] 

机构地区：[1]天津医科大学研究生院,天津300070

出　　处：《第四军医大学学报》2009年第21期2400-2402,共3页Journal of the Fourth Military Medical University

摘　　要：目的:观察黄芪注射液联合博尔泰力注射液用于失代偿期肝硬化的治疗疗效,为临床用药提供科学依据.方法:将80例失代偿期肝硬化患者随机分为治疗组和对照组.治疗组在常规治疗的基础上,另给予黄芪注射液40mL和博尔泰力注射液6mL静脉滴注,1次/d,连用3mo.对照组采用常规治疗.观察实验指标变化和治疗效果.结果:治疗组肝功指标ALT,AST,TBIL,ALB均较治疗前有显著改善(P<0.05),对照组仅ALT,AST有改善(P<0.05);肝纤维化指标水平,治疗组治疗后较治疗前显著下降(P<0.05),且显著低于对照组治疗后(P<0.05);治疗组总有效率为92.5%,对照组总有效率为67.5%,两组比较有统计学差异(P<0.05);两组均无不良反应.结论:黄芪注射液联合博尔泰力注射液能明显控制失代偿期肝硬化的炎症活动,有抗纤维化的作用,治疗效果显著,且无不良反应发生,值得临床推广应用.AIM：To observe the clinical effects of astragalus injection combined with Marine injection treatment in patients with decompensated cirrhosis. METHODS：Eighty cases patients with decompensated cirrhosis were randomly divided into the treatment group and the control group. On the basis of conventional treatment,the treatment group was given the another astragalus injection 40 mL intravenous drip and Marine Injection 6 mL intravenous drip,1 times a day for 3 months,the control group was given conventional therapy, and observation of the changes and treatment of laboratory results. RESULTS ： In the treatment group, the liver function indicators ALT, AST, TBIL, ALB than before treatment have significantly improved （P 〈 0. 05 ）, the control group only ALT, AST has improved （P 〈 0.05 ） ; indicators of the level of liver fibrosis, in the control group, after treatment than before treatment decreased significantly （ P 〈 0.05 ）, but also significantly lower than the control group after treatment （ P 〈 0.05 ） ; the total efficiency of 92.5% in the treatment group, but the total efficiency of 67.5% only in the control group, were more significant difference （ P 〈 0. 05 ） ; no adverse reaction. CONCLUSION： Astragalus injection combined with marine injection could control decompensated cirrhosis of the inflammation, fibrosis of the role of treatment significantly, with no adverse reaction in the 2 groups, worthy of clinical application.

关 键 词：黄芪注射液 博尔泰力射液 失代偿期肝硬化 

分 类 号：R575.2[医药卫生—消化系统]